Find trials
Search tips

Foam Sclerotherapy for the Treatment of Symptomatic Kidney or Liver Cysts in Patients with Autosomal Dominant Polycystic Kidney and Liver Disease

Overview

About this study

The purpose of this study is to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).
 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Age ≥18 years
  2. ADPKD or ADPLD, including patients on investigational therapies for these conditions such as vasopressin receptor antagonists, mTOR inhibitors, and somatostatin analogs
  3. 1-3 large, non-exophytic liver or kidney cyst(s) ≥4cm in all 3 dimensions (cyst volume ≥400cc)
  4. Compressive symptoms from dominant cyst(s) compromising quality of life (as adjudged by the referring Nephrologist or Hepatologist)
  5. Subjects who have had or who will undergo the Foam Sclerotherapy procedure

Exclusion Criteria:

  1. Age <18 years
  2. Absence of ADPKD or ADPLD
  3. Largest cyst <4cm in all 3 dimensions or largest cyst volume <400cc
  4. >3 large, non-exophytic liver or kidney cyst(s) ≥4cm in all 3 dimensions (cyst volume ≥400cc)
  5. Unwilling to comply with study follow-up protocol to 12 ± 1months post-FS
  6. Lacking capacity to provide informed consent to FS of liver or kidney cysts
  7. Pregnancy

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Marie Hogan, M.D., Ph.D.

Closed for enrollment

Contact information:

Kathleen Leistikow

(507) 266-1316

Leistikow.Kathleen@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20381379

Mayo Clinic Footer